CLOSE

Specials

I agree We use cookies on this website to enhance your user experience. By clicking any link on this page you are giving your consent for us to set cookies. More info

Skip to: Curated Story Group 1
Life Sciences Review
US
APAC
CANADA

About Us

Conference

Partner With Us

  • Europe
    • US
    • APAC
    • CANADA
    • LATAM
  • Drug Discovery
    Biotech
    Cancer Immunotherapy
    Cell and Gene Therapy Companies
    Clinical Trial Management
    Drug Discovery and Development
    Genomics
    Therapeutics
    Women's Health
  • Biomanufacturing
    Biomanufacturing
    Bioprocessing
    CDMO
    Clinical Laboratory Services
    CRO
    Supplements
  • Business Services
    Clinical Research Training
    Life Science Consulting
    Life Science Logistics
    Life Science Marketing
  • Leadership Perspectives
  • Innovation Insights
  • News
  • Magazines
×
#

Life Science Review Weekly Brief

Be first to read the latest tech news, Industry Leader's Insights, and CIO interviews of medium and large enterprises exclusively from Life Science Review

Subscribe

loading

Hoffmann & Partner has been recognized by Life Sciences Review Magazine as the exclusive recipient of “Top 10 Life Science Financial Services Companies in Europe - 2024,” based on our proprietary methodology, reflecting its position in the industry. This profile has been developed by the Life Sciences Review research and editorial team based on insights from an interview with , .

Hoffmann & Partner
Shaping Financial Services for Life Sciences Startups

Hoffmann & Partner

Kaspar Kunz, Founding Partner, Hoffmann & PartnerKaspar Kunz, Founding Partner
Switzerland’s rise as the hub for life sciences startups is intrinsically linked to its growing ecosystem of biotech, medtech, and nanotech companies. This thriving ecosystem benefits from substantial investment in research and development, with the Swiss biotech sector marking a milestone with record R&D investments, approximately 3.6 billion dollars in recent years. This signifies not only the sector’s innovative drive but also its commitment to advancing global health technologies.

Amidst the landscape of scientific and technological advancement, the need for robust financial management becomes increasingly critical. This is where niche experts like Hoffmann & Partner come in, offering specialised services through its two primary categories — CFO Services and Corporate Finance.

The CFO Services are tailored for biotech and life sciences startups, which often find the management of financial operations burdensome or outside the purview of their core in-house expertise. Hoffmann & Partner seamlessly fill this gap, offering a broad spectrum of services, which includes accounting, payroll, tax services, controlling, forecasting, and the provision of part-time CFOs. More importantly, the service offers flexibility, much like an online shopping experience, allowing clients to select the level and type of financial management required. This modularity benefits startups that may already have certain financial processes in place but need support only in specific areas.

The other side of the coin is the Corporate Finance services that delve into more strategic financial aspects such as company and compound valuations, support in exit strategies including IPOs and sales, and guidance in financing structuring. The company boasts significant connections within the global M&A landscape, chiefly through its association with AICA, a preeminent network in corporate finance. This affiliation stands as the cornerstone of its corporate finance division, providing a substantial framework for cross-border transactions and strategic alliances.

“While we are not directly engaged in financing, our suite of services is crafted to guide startups from their nascent stages to maturity and potential exit events, offering a comprehensive, end-to-end journey in financial management and strategic planning,” says Kaspar Kunz, founding partner.

These services are also intricately designed to align with the Swiss legal requirements, addressing the startup’s financial compliance needs – maintaining accounting records, preparing annual financial statements, and filing tax returns. As these startups evolve, their financial needs become more complex. Particularly in the life sciences sector, where companies typically experience a phase of substantial cash burn without revenue generation, advanced financial planning becomes crucial. This is where Hoffmann & Partner play a more pivotal role.

While we are not directly engaged in financing, our suite of services is crafted to guide startups from their nascent stages to maturity and potential exit events, offering a comprehensive, end-to-end journey in financial management and strategic planning.

Its expertise lies in translating the intricate details of a startup’s development program into a coherent financial framework. This includes creating detailed forecasts and budgets that provide a clear picture of the financial road ahead. More than just number-crunching, this approach offers profound insights into the company’s financial health, comparing actuals against projections, pinpointing variances, and deciphering the reasons behind them. This level of analysis is invaluable for startups, as it ensures effective management of investor funds and helps identify the point when additional financing is required.

While larger firms offer similar expertise, they may lack the flexibility and cost-effectiveness that startups require. Hoffmann & Partner find their strength in this niche, offering tailored services that resonate well with early-stage startups.

Its advisory role took centre stage for a Basel-based company that initiated its operations with an underdeveloped accounting function. Hoffmann & Partner established the company’s accounting and controlling systems, laying the groundwork for accurate forecasting and expense tracking. As the company matured, Hoffmann & Partner remained an advisor during the client’s exit process, which involved exploring a dual track of selling the company and pursuing an IPO. The team provided the much-needed expertise in creating International Financial Reporting Standards (IFRS) financial statements and drafting the prospectus.

The firm’s involvement concluded successfully with the company’s sale to a major pharmaceutical entity. While this meant the end of services for this particular client, it exemplified Hoffmann & Partner’s successful business model—aiding clients in achieving significant milestones in their corporate narrative.

As Basel’s life sciences and biotech startup ecosystem prioritises efficiency in their financial operations, Hoffmann & Partner wants to remain a partner of choice to optimise their financial operations and contribute to the broader societal advancements in healthcare and biotechnology.

Top 10 Life Science Financial Services Companies in Europe - 2024
Current Issue

Company : Hoffmann & Partner

Management
Kaspar Kunz, Founding Partner

Thank you for Subscribing to Life Science Review Weekly Brief

Life Sciences Review Europe
Follow on LinkedIn

About

  • Home
  • About Us
  • Partner With Us

Stay Connected

  • Subscribe
  • Newsletter
  • Sitemap

Contact Us

  • editor@lifesciencesreview.com
  • sales@lifesciencesreview.com
  • marketing@lifesciencesreview.com

Legal

  • Editorial Policy
  • Privacy Policy
  • Terms of Use

© 2026 Life Sciences Review Europe. All rights reserved. Headquartered in Fort Lauderdale, FL, USA.

This content is copyright protected

However, if you would like to share the information in this article, you may use the link below:

https://www.lifesciencesrevieweurope.com/hoffmann-partner